PP_1170x120_10-25-21

Pharmaceutical Care Management Association (PCMA) president and chief executive officer JC Scott

PCMA issues statement on new Milliman report on insulin coverage

PCMA issues statement on new Milliman report on insulin coverage

WASHINGTON — The Pharmaceutical Care Management Association (PCMA) issued the following statement on a new Milliman report on insulin coverage in Medicare Part D. A new report conducted by the actuarial firm Milliman, “A Summary of Insulin Coverage in Medicare Part D,” shows that insulin products are widely covered on Medicare Part D formularies. “We support

PCMA calls for expanding COVID-19 “Test to Treat” protocols to include pharmacists

PCMA calls for expanding COVID-19 “Test to Treat” protocols to include pharmacists

WASHINGTON — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today issued the following statement supporting the policy of one-stop COVID-19 testing and treatment at pharmacies and calling on the Biden Administration to expand the scope of its recently-announced “Test to Treat” program: “We applaud the Biden administration on its efforts to increase

PCMA makes statement on the Senate Finance Committee hearing on Rx drug prices in Medicare

PCMA makes statement on the Senate Finance Committee hearing on Rx drug prices in Medicare

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott released the following statement on today’s Senate Finance Committee hearing, “Prescription Drug Price Inflation: An Urgent Need to Lower Drug Prices in Medicare.” “PCMA commends the Senate Finance Committee for holding this important hearing on drug price inflation. We share the committee’s goal

PCMA issue statement on the 2023 Medicare Part D proposed rule

PCMA issue statement on the 2023 Medicare Part D proposed rule

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the 2023 Medicare Part D proposed rule from the Centers for Medicare & Medicaid Services (CMS): “We are currently reviewing the proposed rule. However, previous point-of-sale proposals in Medicare have not advanced because they would significantly increase Medicare

PCMA issues statement on drug pricing agreement in the budget bill

PCMA issues statement on drug pricing agreement in the budget bill

WASHINGTON — Pharmaceutical Care Management Association (PCMA) Ppresident and CEO JC Scott issued the following statement on Congress’ agreement on drug pricing language for the budget bill: “We appreciate congressional negotiators’ focus on prescription drug prices and applaud inclusion of repeal of the rebate rule, a rule which threatens to dramatically increase premiums for Medicare

PCMA: Senator Braun’s proposed infrastructure amendment hurts seniors, increases taxpayer costs

PCMA: Senator Braun’s proposed infrastructure amendment hurts seniors, increases taxpayer costs

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the proposed amendment by Senator Mike Braun (R, Ind.) in the Bipartisan Infrastructure Framework (BIF) legislation: “The Senate’s inclusion of a provision to delay the Medicare rebate rule in the infrastructure legislation is a good start to full

PCMA announces Virtual PBM Policy Forum 2021

PCMA announces Virtual PBM Policy Forum 2021

WASHINGTON — Today, the Pharmaceutical Care Management Association (PCMA) announced the Virtual PBM Policy Forum 2021, featuring health care, pharmacy benefit managers (PBMs), and pharmaceutical manufacturer industry thought leaders and executives discussing how the public and private sectors are tackling drug costs and improving the affordability and quality of care for patients. “We are pleased

PCMA: Drug manufacturers’ pricing tactics reduce competition, increase Rx drug costs

PCMA: Drug manufacturers’ pricing tactics reduce competition, increase Rx drug costs

WASHINGTON — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers use “patent thickets” to block generic or biosimilar competition from entering the market. For Humira, Enbrel,

PCMA unveils three-part policy platform to reduce prescription drug costs

PCMA unveils three-part policy platform to reduce prescription drug costs

WASHINGTON — The Pharmaceutical Care Management Association (PCMA) is announcing a new three-part policy platform, supported by America’s pharmacy benefit managers, PBMs, aimed at reducing prescription drug costs by updating Medicare Part D, enhancing competition, and building toward a more value-driven health care system for patients. “PCMA’s multi-faceted policy platform provides specific policy actions to

PCMA praises Biden Administration’s nominees for key Department of HHS positions

PCMA praises Biden Administration’s nominees for key Department of HHS positions

WASHINGTON — Pharmaceutical Care Management Association (PCMA) president and CEO JC Scott issued the following statement on the pending confirmations of three officials of the U.S. Department of Health and Human Services (HHS): Chiquita Brooks-LaSure, nominee for Administrator for the Centers for Medicare & Medicaid Services; Andrea Palm, nominee for Deputy Secretary; Melanie Egorin, nominee

Number of independent pharmacies in U.S. increasing

Number of independent pharmacies in U.S. increasing

WASHINGTON — The number of independent pharmacies in the United States increased in 2020, according to a new analysis of pharmacy data. Pharmacy data from the National Council for Prescription Drug Programs, analyzed by the healthcare analytics firm Quest Analytics, shows the overall number of independent pharmacy stores increased by 449 between January 2020 and

PCMA intros new campaign aimed at repealing the Medicare prescription drug rebate rule

PCMA intros new campaign aimed at repealing the Medicare prescription drug rebate rule

WASHINGTON — The Pharmaceutical Care Management Association (PCMA) unveiled a new campaign commending the Biden Administration for delaying the Medicare prescription drug rebate rule, while calling for a complete Congressional repeal. “We applaud the Biden Administration for delaying the rebate rule’s effective date in order to further examine the rule’s impact on Medicare beneficiaries,” said

Study: Powerful PSAOs negotiate on behalf of independent pharmacies

Study: Powerful PSAOs negotiate on behalf of independent pharmacies

WASHINGTON — A new report, “Pharmacy Services Administrative Organizations (PSAOs) and their Little-Known Connection to Independent Pharmacies,” sheds light on the role of PSAOs in the prescription drug supply and payment chain. The white paper, researched and written by the health care policy consulting firm Health Evaluations and released by the Pharmaceutical Care Management Association

PCMA statement on Senate Finance Committee insulin report

PCMA statement on Senate Finance Committee insulin report

WASHINGTON – The Pharmaceutical Care Management Association (PCMA) released the following statement on the Senate Finance Committee’s report on insulin pricing: “We appreciate the Senate Finance Committee’s focus on insulin pricing and share their urgency in addressing affordability and access for insulin-dependent patients. While we are reviewing the committee’s findings, it’s important to understand that

Adheris Health